QuickView for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=794C421E0D17C6B9A294FB5CD48B15ED;jsessionid=4B4FD6F5E3C512535D7A26EFD8133790;jsessionid=0F13620EC8EFD756F4866FFB29E29BD8;jsessionid=97FBAA4BDA5ED6D0288557B60D8DAE87;jsessionid=AD06BB9D2588CF7111D72E0548590634;jsessionid=D9F0F29EA96FB705E437F70AE88A3E81;jsessionid=30872C9C2D36E73936148D437B3C503A (gene)

1. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistan…
2. Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice.
3. Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Mat…
4. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.
5. Cooperative Nucleotide Binding in Hsp90 and Its Regulation by Aha1.

There were no clinical trials for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=794C421E0D17C6B9A294FB5CD48B15ED;jsessionid=4B4FD6F5E3C512535D7A26EFD8133790;jsessionid=0F13620EC8EFD756F4866FFB29E29BD8;jsessionid=97FBAA4BDA5ED6D0288557B60D8DAE87;jsessionid=AD06BB9D2588CF7111D72E0548590634;jsessionid=D9F0F29EA96FB705E437F70AE88A3E81;jsessionid=30872C9C2D36E73936148D437B3C503A